Nextcell Pharma Ab Stock Current Valuation
| NXTCL Stock | SEK 2.80 0.16 5.41% |
Valuation analysis of NextCell Pharma AB helps investors to measure NextCell Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that NextCell Pharma's price fluctuation is very risky at this time. Calculation of the real value of NextCell Pharma AB is based on 3 months time horizon. Increasing NextCell Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the NextCell stock is determined by what a typical buyer is willing to pay for full or partial control of NextCell Pharma AB. Since NextCell Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of NextCell Stock. However, NextCell Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.8 | Real 2.4 | Hype 2.96 |
The intrinsic value of NextCell Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence NextCell Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of NextCell Pharma AB helps investors to forecast how NextCell stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of NextCell Pharma more accurately as focusing exclusively on NextCell Pharma's fundamentals will not take into account other important factors: NextCell Pharma AB Company Current Valuation Analysis
NextCell Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current NextCell Pharma Current Valuation | 134.94 M |
Most of NextCell Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NextCell Pharma AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, NextCell Pharma AB has a Current Valuation of 134.94 M. This is 99.06% lower than that of the Healthcare sector and 97.1% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 99.19% higher than that of the company.
NextCell Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NextCell Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NextCell Pharma could also be used in its relative valuation, which is a method of valuing NextCell Pharma by comparing valuation metrics of similar companies.NextCell Pharma is currently under evaluation in current valuation category among its peers.
NextCell Fundamentals
| Return On Equity | -0.3 | |||
| Return On Asset | -0.17 | |||
| Operating Margin | (4.75) % | |||
| Current Valuation | 134.94 M | |||
| Shares Outstanding | 34.38 M | |||
| Shares Owned By Insiders | 42.82 % | |||
| Shares Owned By Institutions | 5.27 % | |||
| Price To Book | 2.01 X | |||
| Price To Sales | 37.14 X | |||
| Revenue | 5.59 M | |||
| Gross Profit | (2.49 M) | |||
| EBITDA | (34.08 M) | |||
| Net Income | (35.02 M) | |||
| Cash And Equivalents | 150.75 M | |||
| Cash Per Share | 4.39 X | |||
| Current Ratio | 42.29 X | |||
| Book Value Per Share | 3.10 X | |||
| Cash Flow From Operations | (33.31 M) | |||
| Earnings Per Share | (0.81) X | |||
| Number Of Employees | 15 | |||
| Beta | 0.43 | |||
| Market Capitalization | 255.91 M | |||
| Total Asset | 124.66 M | |||
| Net Asset | 124.66 M |
About NextCell Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NextCell Pharma AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NextCell Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NextCell Pharma AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NextCell Stock Analysis
When running NextCell Pharma's price analysis, check to measure NextCell Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCell Pharma is operating at the current time. Most of NextCell Pharma's value examination focuses on studying past and present price action to predict the probability of NextCell Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCell Pharma's price. Additionally, you may evaluate how the addition of NextCell Pharma to your portfolios can decrease your overall portfolio volatility.